COMPANY:

Harbinger Health

"Harbinger Health...today announced the presentation of four abstracts at clinical and scientific meetings for cancer research and data science. Three abstracts were presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation in San Diego, California from November 13-16, 2024, and an additional abstract was presented at the Cold Spring Harbor Laboratory Biological Data Science meeting in Cold Spring Harbor, New York from November 13-16, 2024."

"Harbinger Health...announced a new collaboration with Memorial Sloan Kettering Cancer Center (“MSK”), one of the world’s largest leading cancer centers, to advance the Company’s blood-based early cancer detection platform."

"Harbinger Health...announced...a research agreement with the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute to advance the Company's technology for early-stage multi-cancer detection...With this agreement, Harbinger and the Hale Family Center will jointly conduct a clinical study of participants at high risk for cancer due to a family history of pancreatic cancer."

"Harbinger Health...announced today that it raised $140 million in Series B funding....The new funds will be used to support the completion of Harbinger's Cancer ORigin Epigenetics-Harbinger Health (CORE-HH) 10,000-participant clinical study of its novel blood-based cancer screening platform; develop its two-tier testing model; expand its data science and commercial teams and capabilities; and initiate additional clinical studies in high-risk populations....The Company expects to launch its first product – a laboratory developed test (LDT) for the detection of early cancer – in 2025."